11.2 Protocol Submission, Approval & Amendment Processes

Protocol Submission, Approval & Amendment Processes

Quick Reference: In the ICH E6(R3) glossary, "the term 'protocol' refers to protocol and protocol amendments", and a protocol amendment is "a documented description of a change(s) to a protocol." There is no such thing as an informal amendment. If the change is not documented and approved, it is not an amendment — it is a deviation.

Why this is tested

The ACRP-CP Exam Content Outline lists 2G, "Protocol submission, approval, and amendment processes" in Domain 2, and the task statements include "Coordinate protocol and/or protocol amendments through appropriate approval processes (e.g., IRB/IEC, sponsor, regulatory authority)" and "Implement the administrative and/or clinical tasks for protocol amendments."

---

Part 1 — Getting to first enrolment

Two approval streams run in parallel and both must complete before anyone is enrolled.

        SPONSOR develops protocol (Appendix B contents)
                        │
        ┌───────────────┴────────────────┐
        │                                │
  REGULATORY STREAM              ETHICS STREAM
  Annex 1 §3.8.1                 Annex 1 §1 and §3.8.2
  Sponsor (or sponsor and        Submission by investigator/
  investigator) submits any      institution or sponsor per
  required application to the    applicable requirements
  appropriate authority for
  review, acceptance and/or      IRB/IEC review of protocol,
  permission to begin            ICF, recruitment material,
                                 IB, investigator qualifications
        │                                │
  Permission / acceptance        Documented approval or
  to begin the trial             favourable opinion
        └───────────────┬────────────────┘
                        │
      Both complete + contract executed + site greenlight
                        │
                   FIRST PARTICIPANT ENROLLED

Annex 1 section 1.4.6 is categorical: the IRB/IEC must specify "that no participant should be enrolled in a trial before the IRB/IEC issues its documented approval/favourable opinion of the trial."

Note the word documented. A chair's verbal assurance, an email saying "it went through", or minutes not yet issued are not approval. The site holds a dated approval letter identifying the exact protocol version and the exact consent form version.

What the IRB/IEC reviews

• The protocol and any amendments
• The informed consent form and any assent documents, in the languages to be used
• Recruitment materials — advertisements, scripts, screening questionnaires
• The Investigator's Brochure or equivalent product information
• Investigator qualifications, typically the current curriculum vitae
• Participant payment and reimbursement arrangements
• Any participant-facing materials such as diaries and instruction sheets
• Information on funding sources and conflicts of interest

Version control is the site's job

Every approved document has a version number and a date. The consent form in the drawer must be the version named in the approval letter. Site staff should be able to answer, without hesitation, which protocol version is currently in force, which consent version each participant signed, and when each was approved.

---

Part 2 — Amendments

The default rule and its two exceptions

Annex 1 section 1.4.7 requires the IRB/IEC to specify "that no deviations from or changes to the protocol should be initiated without prior documented IRB/IEC approval/favourable opinion of an appropriate protocol amendment except when necessary to eliminate immediate hazards to the participants or, in accordance with applicable regulatory requirements, when the change(s) involves only logistical or administrative aspects of the trial."

Read as a decision:

Exam Watchout: The immediate-hazard exception is narrow and is about hazard, not inconvenience, recruitment pressure or operational difficulty. A participant developing a dangerous laboratory abnormality who needs a dose held outside the protocol's rules is an immediate hazard. A site that cannot recruit under the current criteria is not.

The immediate-hazard pathway

Annex 1 section 2.5.4: the investigator "should follow the protocol and deviate only where necessary to eliminate an immediate hazard(s) to trial participants. In case of deviations undertaken to eliminate immediate hazard to trial participants, the investigator should inform the sponsor promptly."

Annex 1 section 2.5.5: the investigator "should report information on the immediate hazard, the implemented change and the subsequent proposed protocol amendment, if any, to the IRB/IEC and, where applicable, regulatory authorities."

Immediate hazard identified
        │
1. ACT to protect the participant — do not wait for approval
        │
2. DOCUMENT in the source record: the hazard, what was done, the clinical rationale
        │
3. INFORM THE SPONSOR PROMPTLY (§2.5.4)
        │
4. REPORT to the IRB/IEC and, where applicable, regulatory authorities:
   the hazard · the change implemented · the proposed amendment, if any (§2.5.5)
        │
5. AMEND the protocol if the change needs to become permanent

Substantial versus administrative changes

Annex 1 section 1.4.5 permits the IRB/IEC to provide "expedited review and approval/favourable opinion of minor change(s) in ongoing trials" that already hold its approval, in accordance with applicable regulatory requirements. The IRB/IEC decides whether a change is minor — the sponsor's or site's label does not bind it.

Design out the need for amendments

Appendix B makes a point worth carrying into practice: "Building adaptability into the protocol, for example, by including acceptable ranges for specific protocol provisions, can reduce the number of deviations or in some instances the requirement for a protocol amendment. Such adaptability should not adversely affect participant safety or the scientific validity of the trial."

A protocol that specifies "day 28" generates deviations; one that specifies "day 28 ± 3 days" does not, without any loss of scientific integrity. This is Principle 8 — clear, concise and operationally feasible — applied at the drafting stage.

---

Part 3 — The amendment cascade

Approving an amendment is the beginning of the work, not the end. Each of the following must be handled and evidenced:

Exam Watchout: The most common site failure is implementing an amendment on the date the sponsor issued it rather than the date the local IRB/IEC approved it. Sites in a multicentre trial will lawfully be running different protocol versions for a period, and that is correct — each site follows the version approved for it.

---

Realistic exam scenario

Scenario: A sponsor emails all sites on 3 March with amendment 4, which adds a mandatory electrocardiogram at every visit after two participants elsewhere developed QTc prolongation, and lowers the maximum permitted dose. The email says "effective immediately." A coordinator schedules ECGs from the following day. Her site's IRB approves amendment 4 on 24 March. Between 4 and 24 March, six participants attend visits: five receive the new ECG, and one is dose-reduced under the new maximum.

Evaluation — the two changes are not the same:

• The dose reduction is defensible if it was necessary to eliminate an immediate hazard to that specific participant. Under section 2.5.4 the investigator may deviate for that reason, must inform the sponsor promptly, and under 2.5.5 must report the hazard, the change and the proposed amendment to the IRB/IEC and, where applicable, regulatory authorities. The clinical rationale must be documented in the source record.
• Performing the five additional ECGs before local approval is not covered by either exception. An ECG is a study procedure the participants did not consent to and the IRB had not approved. "The sponsor said effective immediately" carries no weight against section 1.4.7 — the sponsor cannot approve on the IRB's behalf.

Correct actions: stop implementing amendment 4 until the local approval date; document the five pre-approval ECGs as protocol deviations and report them to the IRB/IEC and sponsor; assess whether any participant was placed at risk or incurred an unconsented procedure; determine whether the revised consent form requires re-consent of currently enrolled participants and complete it before their next visit; confirm the registry entry reflects the changed design; document retraining on version 4; and raise a CAPA establishing that at this site amendments take effect on the local IRB approval date, communicated to the sponsor as feedback on its "effective immediately" language.